No elevations of liver transaminase levels during, at the end of treatment and at follow-up week 12 (ALT = 16 ± 3.74, 11.14 ± 5.7, 21.83 ± 13.44 U / L, respectively; and AST=18±6.74, 13.86 ± 3.85, 21 ± 7.77 U / L, respectively) compared with baseline (ALT = 73.9 ± 8.79, AST=54.1±5.71 U/L).